Monoclonal Antibodies 19th & 20th March 2013

Feb. 3, 2013 - PRLog -- Generating annual sales of almost $50bn per year monoclonal antibodies continue to play a vital role in the biopharmaceutical development and represent 42% of the total market. Anticipated steady growth at an annual rate of 6.9% suggests the revenues will reach over $63bn/year by 2015. Primarily driven by the oncology and autoimmune disease treatments, the industry’s window will be significantly widened by the introduction of mAbs with novel indications and increasing penetration of the emerging economies.

Appel are proud to present our 2nd annual  Monoclonal Antibodies conference, due to take place on Tuesday 19th and Wednesday 20th March 2013, London, UK. Versatility of monoclonal antibodies and their advantages over conventional drugs, such as their specificity, indicate there is immense scope for research and therapeutic applications.

For further information visit our website:
http://www.appelconsulting.co.uk/events.php?prop_id=182

Conference chairs:
•   Dr Yasmina Abdiche, Associate Research Fellow, Pfizer USA
Key presenters include:
•Dr Carrie Enevar, Investigator, GlaxoSmithKline
• Dr Steffen Hartmann, Head of Protein Deveopability, Novartis
• Dr Rebecca Croasdale, Oncology Scientist, HoffmannLaRoche
• Dr Olga Obrezanova, Principle Scientist, Lonza Biologics
• Dr Marcel Kuiper, Senior Scientist, MedImmune
• Dr Nicola Beltraminelli, Head of Antibody Discovery Unit, Vivalis
• Dr Richard Schasfoort, CSO, IBIS Technologies B.V
• Dr Pim Hermans, Director of Ligand Discovery, BAC bv
• Dr Brian Burke, Business Development Manager, Horizon Discovery Ltd
• Dr Mark Throsby, Chief Operating Officer, Merus
• Dr Hans de Haard, Chief Scientific Officer, Argenx
• Dr Maria G‐Pajuelo, Chief Scientific Officer, Fairjourney Biologics

To download agenda click here:
http://www.jcpeters-demos.info/appel/monoclonal_antibodies_2013.pdf

To register complete final page of agenda and email this to sabrina.daw1@appelconsulting.co.uk

# # #

Appel Consulting have had an established portfolio of Pharmaceutical events.
Appel Consulting is at the forefront of producing the highest quality international pharmaceutical events. All of the events we organise are highly focused towards senior level executives.

Our conferences are all research driven to enable our clients to remain at the cutting edge of business information. Appel Consulting events offer clients key opportunities to network within the pharmaceutical sector.